Author(s): Cruciani F, De Crescenzo F, Vecchi S, Saulle R, Mitrova Z, Amato L, Davoli M.
Question: Should Azithromycin compared to Clarithromycin be used for COVID-19 patients?
Setting: Outpatient

№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Azithromycin	Clarithromycin	Relative (95% CI)	Absolute (95% CI)	Certainty
			Certainty assessment				**№ of patients**		**Effect**		

Number of patients with significant improvement in lung disease on CT

№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Azithromycin	Clarithromycin	Relative (95% CI)	Absolute (95% CI)	Certainty
1 [1]	randomised trials	serious a	not serious	not serious	not serious	none	70/107 (65.4%)	76/99 (76.8%)	**RR 0.85** (0.72 to 1.02)	**115 fewer per 1.000** (from 215 fewer to 15 more)	⊕⊕⊕◯ MODERATE

Time to SARS-CoV 2 clearance

№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Azithromycin	Clarithromycin	Relative (95% CI)	Absolute (95% CI)	Certainty
1 [1]	randomised trials	serious a	not serious	not serious	not serious	none	107	99	-	**SMD 0.15 higher** (0.13 lower to 0.42 higher)	⊕⊕⊕◯ MODERATE

Explanations

a. Downgraded of one level for unclear risk of selection, performance and detection bias

References

1. Rashad A, Nafady A, Hassan MH, Mansour H, Taya U, Bazeed SES et al. Therapeutic efficacy of macrolides in management of patients with mild COVID-19, 01 February 2021, PREPRINT (Version 1) available at Research Square [https://doi.org/10.21203/rs.3.rs-181996/v1].